| Literature DB >> 35114865 |
Yohannes Tekalegn1, Biniyam Sahiledengle1, Demelash Woldeyohannes2, Daniel Atlaw3, Sisay Degno3, Fikreab Desta1, Kebebe Bekele4, Tesfaye Aseffa5, Habtamu Gezahegn6, Chala Kene7.
Abstract
BACKGROUND: Cervical cancer is the fourth most common cancer among women. High parity has long been suspected with an increased risk of cervical cancer. Evidence from the existing epidemiological studies regarding the association between parity and cervical cancer is variable and inconsistent. Therefore, the objective of this systematic review and meta-analysis was to synthesize the best available evidence on the epidemiological association between parity and cervical cancer.Entities:
Keywords: case–control; cervical cancer; meta-analysis; parity; systematic review
Mesh:
Year: 2022 PMID: 35114865 PMCID: PMC8819811 DOI: 10.1177/17455065221075904
Source DB: PubMed Journal: Womens Health (Lond) ISSN: 1745-5057
Figure 1.PRISMA flowchart of the article selection process for systematic review and meta-analysis of the association between cervical cancer and parity.
List of studies included in the systematic review and meta-analysis of the association between parity and risk of cervical cancer, 2020.
| Primary author | Year of publication | Study period | Country | Study setups/source | Study design | Number of cases | Number of controls | Age range (years) |
|---|---|---|---|---|---|---|---|---|
| Cai et al.
| 2008 | 2003–2005 | China | Hospital | Case–control | 110 | 110 | 22–72 |
| Adjorlolo-Johnson et al.
| 2010 | April 1997 to October 1999 | Côte d’Ivoire | Hospital | Case–control | 132 | 120 | 18–70 |
| Bezabih et al.
| 2015 | April 1 to 30 September 2010 | Ethiopia | Hospital | Case–control | 60 | 120 | Unreported |
| Franceschi et al.
| 2003 | June 1998 to May 1999 | India | Hospital | Case–control | 193 | 210 | Unreported |
| Sharma and Pattanshetty
| 2018 | Unreported | India | Hospital | Case–control | 91 | 182 | 20–80 |
| Thakur et al.
| 2015 | July 2008 to October 2009 | India | Hospital | Case–control | 226 | 226 | Unreported |
| Arfailasufandi et al.
| 2019 | October to December 2018 | Indonesia | Hospital | Case–control | 100 | 100 | Unreported |
| Putri et al.
| 2019 | March 2016 to August 2016 | Indonesia | Hospital | Case–control | 60 | 60 | 21–30 |
| Chen et al.
| 2005 | 1986–1992 | Taiwan | Hospital | Case–control | 45 | 54 | <36 |
| Natphopsuk et al.
| 2012 | February 2009 to August 2011 | Thailand | Hospital | Case–control | 177 | 177 | 27–81 |
| Green et al.
| 2003 | 1984–1989 | The United Kingdom | Cancer registry | Case–control | 180 | 923 | 20–44 |
| Green et al.
| 2003 | The United Kingdom | Cancer registry | Case–control | 180 | 923 | 20–44 | |
| Muñoz et al.
| 2002 | Unreported | Multicenter | Hospital | Case–control | 1673 | 253 | Unreported |
Primary studies with available adjusted odds ratios of the association between parity and cervical cancer.
| Primary author | Year of publication | Parity | AOR (95% CI) | Adjusted confounders |
|---|---|---|---|---|
| Adjorlolo-Johnson et al.
| 2010 | >2 | 5.1 (1.2–21.9) |
|
| Arfailasufandi et al.
| 2019 | ⩾3 | 3.94 (1.47–10.59) | Unreported |
| Bezabih et al.
| 2015 | 3 to 4 | 4.7 (0.8–27.2) | Unreported |
| Bezabih et al.
| 2015 | >4 | 12.4 (2.4–64.2) | |
| Cai et al.
| 2008 | 2 | 6.05 (0.93–38.59) | Unreported |
| Cai et al.
| 2008 | 3 | 9.06 (1.32–62.52) | |
| Cai et al.
| 2008 | >3 | 16.82 (18.1–150.95) | |
| Chen et al.
| 2005 | ⩾3 | 4.18 (0.71–24.69) | Unreported |
| Franceschi et al.
| 2003 | 0 | 0.5 (0.1–2.1) |
|
| Franceschi et al.
| 2003 | 3–4 | 2.6 (1.6–4.3) | |
| Franceschi et al.
| 2003 | 5–6 | 5.7 (3.0–11.1) | |
| Franceschi et al.
| 2003 | ⩾7 | 5.7 (2.4–13.3) | |
| Green et al.
| 2003 | 1 | 1.27 (0.69–2.34) |
|
| Green et al.
| 2003 | 2 | 1.14 (0.63–2.05) | |
| Green et al.
| 2003 | ⩾3 | 1.44 (0.76–2.73) | |
| Green et al.
| 2003 | 1 | 0.88 (0.55–1.4) | |
| Green et al.
| 2003 | 2 | 1.41 (0.92–2.17) | |
| Green et al.
| 2003 | ⩾3 | 1.86 (1.16–2.99) | |
| Natphopsuk et al.
| 2012 | ⩾3 | 1.63 (0.62–4.28) | Unreported |
| Putri et al.
| 2019 | ⩾3 | 2.89 (1.18–7.1) | Unreported |
| Sharma and Pattanshetty
| 2018 | 3–5 | 4.66 (2.04–10.66) | Unreported |
| Sharma and Pattanshetty
| 2018 | ⩾6 | 10.12 (4.33–23.87) | |
| Thakur et al.
| 2015 | ⩾3 | 1.7 (1.25–2.65) | Unreported |
| Muñoz et al.
| 2002 | 1–2 | 1.81 (1.31–2.52) |
|
| Muñoz et al.
| 2002 | 3–4 | 2.55 (1.95–3.34) | |
| Muñoz et al.
| 2002 | 5–6 | 2.83 (2.02–3.96) | |
| Muñoz et al.
| 2002 | ⩾7 | 3.82 (2.66–5.48) |
AOR: adjusted odds ratio; CI: confidence interval.
indicates age, low socioeconomic status, and lifetime number of sex partners.
indicates age and area of residence.
indicates age, recruitment center, age at first intercourse, duration of oral contraceptive use, level of education, number of negative screening results, smoking status and total number of sexual partners.
indicates study center, age, education, smoking status, age at first intercourse, number of sexual partners, oral contraceptive use, and history of Papanicolaou’s smears.
Figure 2.Forest plot of the individual and pooled odds ratios (OR) of association between cervical cancer and parity.
Figure 3.Sensitivity analysis for the pooled estimate of the association between parity and cervical cancer.
Meta-regression of factors associated with the heterogeneity of the studies included in estimating the pooled effect of parity on cervical cancer.
| Variables | OR (95% CI) | |
|---|---|---|
| Year of publication | 1.0 (1.001–1.1) | 0.04 |
| Age of participants | 0.84 (0.68–1.02) | 0.08 |
| Study setup | 0.39 (0.22–0.66) | 0.001 |
| Definition of parity | 1.02 (0.94–1.10) | 0.5 |
| Factors adjusted for confounder | 0.77 (0.60–0.98) | 0.03 |
OR: odds ratio; CI: confidence interval.
Significant at p < 0.05.
Subgroup analysis of the association between parity and cervical cancer.
| Variables | Subgroup | Number of studies | AOR (95% CI) | Heterogeneity across the studies | Heterogeneity between groups
( | |
|---|---|---|---|---|---|---|
| Country | China | 1 | 12.6 (5.39–29.46) | 0 | <0.001 | <0.001 |
| Côte d’Ivoire | 1 | 5.1 (1.2–21.9) | 0 | <0.001 | ||
| Ethiopia | 1 | 7.9 (2.37–26.28) | 0 | 0.43 | ||
| India | 3 | 3.45 (1.95–6.12) | 79.4 | <0.001 | ||
| Indonesia | 2 | 3.32 (1.71–6.46) | 0 | 0.64 | ||
| Multicenter | 1 | 2.64 (1.99–3.5) | 67.8 | 0.025 | ||
| Taiwan | 1 | 4.18 (0.71–24.65) | 0 | – | ||
| Thailand | 1 | 1.63 (0.62–4.28) | 0 | – | ||
| The United Kingdom | 1 | 1.30 (1.05–1.62) | 5.8 | 0.37 | ||
| Year of publication | 2000–2010 | 6 | 2.39 (1.80–3.16) | 77.1 | <0.001 | 0.16 |
| 2011–2020 | 6 | 3.71 (2.12–6.51) | 68.4 | 0.002 | ||
| Study setups | Hospital | 11 | 3.45 (2.66–5.48) | 65.8 | 74.6 | <0.001 |
| Registry | 1 | 1.30 (1.04–1.62) | 5.8 | – | ||
| Factors adjusted in multivariate model |
| 1 | 5.1 (1.19–21.79) | 0 | – | <0.001 |
|
| 1 | 3.11 (1.47–6.58) | 72.8 | 0.012 | ||
|
| 1 | 1.3 (1.05–1.62) | 5.8 | 0.37 | ||
|
| 1 | 2.64 (1.99–3.5) | 67.8 | 0.025 | ||
| e | 8 | 4.67 (2.74–7.96) | 68.5 | <0.001 | ||
AOR: adjusted odds ratio; CI: confidence interval.
indicates age, low socioeconomic status, and lifetime number of sex partners.
indicates age and area of residence.
indicates age, recruitment center, age at first intercourse, duration of oral contraceptive use, level of education, number of negative screening results, smoking status, and total number of sexual partners.
indicates study center, age, education, smoking status, age at first intercourse, number of sexual partners, oral contraceptive use, and history of Papanicolaou’s smears.
Figure 4.Funnel plot for the meta-analysis of the association between parity and cervical cancer.